I wish for the patients involved that this was a miracle cure for blindness, but strictly from an investment perspective, Dry AMD is a $30 billion market, and that doesn't even include other treatments that ACT has in the pipeline should the use of embryonic stem cells for Stagardt's and Dry AMD eventually be approved by the FDA.
Pertaining to the expectations people have, I believe I discussed here previously that this treatment would likely not nor was it intended to reverse the vision loss patients have already suffered, but rather was meant to slow or stop the progression of the disease so the patients didn't lose any more vision than they already had, and someone (I believe it was someone who doesn't post here regularly but I don't recall) was implying that could/should. Oh well, whatever.
